$BEAM

$25.45▲ -1.6% YTD

8 SEC 13D/G filings tracked · Last updated Nov 3, 2026

Filing History

CP $25.45▲ -1.6%Nov 3, 2026 · ThinkSabio Blog

$BEAM - Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio…

News

BEAM ▼ -0.5% - Beam Therapeutics Inc.

CP $23.66▲ -0.5%Oct 27, 2026 · ThinkSabio Blog

$BEAM - Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Gly…

News

BEAM ▲ +1.3% - Beam Therapeutics Inc.

CP $25.47▲ +1.3%Oct 13, 2026 · ThinkSabio Blog

$BEAM - Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annua…

News

BEAM ▲ +2.7% - Beam Therapeutics Inc.

CP $25.87▲ +2.7%Sep 10, 2026 · ThinkSabio Blog

$BEAM Cathie Wood's ARK Investment buys 271K shares of Beam Therapeutics…

News

BEAM ▲ +3.7% - Beam Therapeutics Inc.

CP $30.75▲ +3.7%Sep 8, 2026 · ThinkSabio Blog

$BEAM Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)…

News

BEAM ▲ +3.5% - Beam Therapeutics Inc.

CP $30.70▲ +3.5%Sep 8, 2026 · ThinkSabio Blog

$BEAM - Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European…

News

BEAM ▼ -0.8% - Beam Therapeutics Inc.

CP $29.21▲ -0.8%Sep 1, 2026 · ThinkSabio Blog

$BEAM - Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer…

SEC 13D/G

BEAM - Beam Therapeutics Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks Simplified

$27.00▼ -0.55%Aug 13, 2026 · ThinkSabio Blog

$BEAM SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #BEAM Beam Therapeutics Inc. : $27.00 Sector: Healthcare | YTD:…